Mytesi

Antiretroviral Therapy, Diarrhea

Treatment

3 FDA approvals

1 Active Study for Mytesi

Treatment for

Antiretroviral Therapy

What is Mytesi

CrofelemerThe Generic name of this drug

Treatment SummaryCrofelemer, also known as Fulyzaq, is a drug made from the bark of the Croton lechleri tree found in the Amazon rainforest. It is used to treat symptoms of non-infectious diarrhea in adults with HIV/AIDS who are taking antiretroviral therapy.

Fulyzaqis the brand name

Mytesi Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Fulyzaq

Crofelemer

2012

Approved as Treatment by the FDA

Crofelemer, commonly known as Fulyzaq, is approved by the FDA for 3 uses like Noninfectious diarrhea and Antiretroviral Therapy .

Noninfectious diarrhea

Antiretroviral Therapy

Diarrhea

Effectiveness

How Mytesi Affects PatientsCrofelemer helps to reduce diarrhea by blocking a protein that helps the body lose too much water. Unlike other drugs, it does not make diarrhea worse when treatment ends, does not disrupt the body's natural movements, and is not absorbed into the bloodstream, so it has fewer chances of causing side effects or interacting with other drugs.

How Mytesi works in the bodyCrofelemer works by blocking two channels in the intestinal cells, CFTR and CaCC. This prevents fluid from leaving the body too quickly, which can help reduce diarrhea. It does this by blocking chloride, a type of salt, from passing out of the cells.

When to interrupt dosage

The suggested measure of Mytesi is contingent upon the established condition. The amount of dosage changes, depending upon the delivery approach detailed in the table beneath.

Condition

Dosage

Administration

Antiretroviral Therapy

125.0 mg,

Oral, , Tablet, coated, Tablet, coated - Oral

Diarrhea

125.0 mg,

Oral, , Tablet, coated, Tablet, coated - Oral

Warnings

Common Mytesi Drug Interactions

Drug Name

Risk Level

Description

Mytesi Toxicity & Overdose RiskCommon side effects of this drug include coughing, bloating, upper respiratory infection, bronchitis, and jaundice.

image of a doctor in a lab doing drug, clinical research

Mytesi Novel Uses: Which Conditions Have a Clinical Trial Featuring Mytesi?

An active clinical trial is presently exploring the use of Mytesi to manage Diarrhea.

Condition

Clinical Trials

Trial Phases

Antiretroviral Therapy

1 Actively Recruiting

Phase 2

Diarrhea

0 Actively Recruiting

Patient Q&A Section about mytesi

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does Mytesi treat?

"Mytesi is an antidiarrheal drug that can be used to help relieve symptoms of noninfectious diarrhea in adult patients with HIV/AIDS who are receiving antiretroviral therapy (ART)."

Answered by AI

When was Mytesi FDA approved?

"announced that the FDA had approved Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

Mytesi FDA Approval History Mytesi (crofelemer) is a proanthocyanidin oligomer indicated to relieve symptoms of diarrhea in HIV/AIDS patients taking antiretroviral therapy. Mytesi (crofelemer) was first approved as Fulyzaq in December 2012. In October 2016, Napo Pharmaceuticals, Inc. announced that the FDA had approved Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy."

Answered by AI

How long does it take Mytesi to work?

"When will my symptoms start to improve? After 4 weeks of treatment with Mytesi, most patients see a reduction in the frequency of watery bowel movements. When taken daily, patients usually continue to see improvement in their symptoms for up to 20 weeks."

Answered by AI